Obesity Treatment

SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion

SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion

SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.

May 11, 2026
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44

SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44

SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.

May 11, 2026
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach

SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach

SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.

April 24, 2026